Navigation Links
Epiphany Announces Positive Results from Its Phase 2b Trial in Shingles.
Date:11/18/2009

SAN FRANCISCO, Nov. 18 /PRNewswire/ -- Epiphany Biosciences announced results from its Phase 2b dose-ranging study of EPB-348 (valomaciclovir) in patients with shingles (herpes zoster) infection. The study's primary endpoint was non-inferiority of once-daily valomaciclovir compared to thrice-daily valacyclovir in terms of time to complete crusting of the shingles rash. The double-blinded study enrolled 373 patients, randomized into 3 arms: 1 gram of once-daily EPB-348, 2 grams of once-daily EPB-348, thrice-daily valacyclovir (1 gram, three times per day). Eighteen patients also received 3 grams of once-daily EPB-348.

Once-daily EPB-348 at two grams met its primary endpoint of non-inferiority to valacyclovir. Valomaciclovir (EPB-348) was also non-inferior to valacyclovir in the secondary endpoints of time to complete pain resolution, time to rash resolution and time to cessation of new lesion formation. The highest dose of valomaciclovir (3 grams once daily) demonstrated superiority to valacyclovir with regards to the primary endpoint (p-value < 0.007).

Dose-dependent trends to improved pain resolution in the subset of treated patients who were over 50 years old and trends to faster resolution of severe pain in patients of all ages were seen in the higher dose EPB-348 treatment arms when compared to valacyclovir. All doses of EPB-348 showed improvement over valacyclovir for patients presenting for first treatment towards the end of the 72 hour treatment window. Currently-approved shingles treatments are effective only within the first 72 hours of rash appearance.

"These Phase 2 data indicate that once-daily valomaciclovir could be more convenient than three times daily valacyclovir for the treatment of herpes zoster, and it is equally safe. Moreover, the 3 gram dose of valomaciclovir was superior to valacyclovir in terms of clinical efficacy. Therefore, Phase 3 studies with larger numbers of patients are clea
'/>"/>

SOURCE Epiphany Biosciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Epiphany Biosciences Reports Initiation and Enrollment in Valomaciclovir Study for Shingles
2. Epiphany Biosciences Reports Initiation of Phase 2 Study of Valomaciclovir for the Treatment of Acute Infectious Mononucleosis
3. Epiphany Biosciences to Continue Phase 2 Shingles Study After Interim Analysis; Plans Follow-On Clinical Trial Studying Post-Herpetic Neuralgia (PHN)
4. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
5. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
6. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
7. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
8. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
9. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
10. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
11. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014 The Cadence Fitness & ... Center by the Medical Fitness Association, a non-profit organization ... their full potential. The Cadence Fitness & Health Center ... suburbs and second in the Chicagoland area. ...
(Date:1/15/2014)... 2014 Reportlinker.com announces that a new ... catalogue: PharmaPoint: Atopic ... Analysis to 2022 http://www.reportlinker.com/p01957657/PharmaPoint-Atopic-Dermatitis---India-Drug-Forecast-and-Market-Analysis-to-2022.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology ... India Drug Forecast and Market Analysis to ...
(Date:1/15/2014)... YORK , Jan. 15, 2014 ... market research report is available in ... Global Markets and Technologies for Advanced ... Routes of Administration ...
Breaking Medicine Technology:Cadence Fitness & Health Center Certified as Medical Fitness Facility 2Cadence Fitness & Health Center Certified as Medical Fitness Facility 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 16
... 14, 2011 Cornerstone Pharmaceuticals, Inc., a leader ... of a preclinical toxicity study of azide drug-loaded ... Institute (NCI) under a Collaboration Agreement. Emulsiphan is ... "We are so pleased that Cornerstone has received ...
... 14, 2011 (Nasdaq: VRML ) –Vermillion, ... OVA1® as part of the recently published ACOG/SGO committee ... Gynecology , the American College of Obstetricians and Gynecologists ... update committee opinion on the role of the obstetrician-gynecologist ...
Cached Medicine Technology:Cornerstone Pharmaceuticals Announces Positive Results of Emulsiphan Safety Study 2Cornerstone Pharmaceuticals Announces Positive Results of Emulsiphan Safety Study 3OVA1 Included in Latest ACOG/SGO Committee Opinion 2OVA1 Included in Latest ACOG/SGO Committee Opinion 3OVA1 Included in Latest ACOG/SGO Committee Opinion 4
(Date:4/17/2014)... first genetic variant specifically associated with the risk ... 10-15 per cent of all breast cancer cases. ... cancer sub-type, called invasive lobular carcinoma, gives researchers ... particular kind of breast cancer, which can be ... (Thursday) in the journal PloS Genetics , ...
(Date:4/17/2014)... Researchers at the University of California, San Diego School ... those who have suffered a recent major loss are ... older adults. , The study is published in this ... Psychiatry . , Because compassionate behaviors are associated with ... findings offer insights into ways to improve the outcomes ...
(Date:4/17/2014)... New Rochelle, NY, April 17, 2014U.S. military personnel ... "blast plus impact" concussive traumatic brain injury (TBI) ... were evacuated for other medical reasons. Differences in ... and depression 6-12 months after injury are reported ... , a peer-reviewed journal from Mary Ann Liebert, ...
(Date:4/17/2014)... Calif., April 17, 2014 By discovering a new ... after a stroke, researchers at UC Irvine and the ... that may limit or prevent stroke-induced brain damage. , ... fourth-leading cause of death and primary reason for disability ... in a stroke and lets blood-borne material into the ...
(Date:4/17/2014)... Arias, M.D., Ph.D., at The University of Texas Health ... superbug that caused a bloodstream infection in a Brazilian ... of The New England Journal of Medicine . ... of highly-resistant bacteria known as methicillin-resistant Staphylococcus aureus ... hospital and community-associated infections. The superbug has also acquired ...
Breaking Medicine News(10 mins):Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 2Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 3Health News:The ilk of human kindness 2Health News:Long-term effects of battle-related 'blast plus impact' concussive TBI in US military 2Health News:Study IDs new cause of brain bleeding immediately after stroke 2Health News:New MRSA superbug emerges in Brazil 2
... 15, 2010) -- Next week the city of Philadelphia ... Association of Physicists in Medicine (AAPM), the premier organization ... encompassing physics principles and applications in medicine and biology. ... meeting are focused on patient safety -- tailoring therapy ...
... as soldiers in 86 countries across the globe, almost ... how these children adjust after they return to their ... the characteristics of the communities to which the children ... former child soldiers from Sierra Leone who lived in ...
... Barcelona, Spain Today during the 88th General Session ... in Barcelona, Spain, presenting author S. Pradhani, University of ... Acinar Cells Regenerate Functional Glandular Structures in Modified Hydrogels." ... an ECM modified hyaluronic acid (HA) based hydrogel culture ...
... CHAPEL HILL Dozens of UNC researchers are heading ... AIDS conference this week. The International AIDS Society ... to discuss progress and chart a course for stemming ... Bill Clinton will address an estimated 25,000 attendees at ...
... By Karen Pallarito HealthDay Reporter , ... readmitted within 30 days of a hospital stay, it ... and wasteful spending on the hospital,s part. ... Cleveland Clinic researchers challenge that conventional wisdom. Their calculations ...
... has selected five physicians as recipients of two ... the Junior Faculty Career Research Training Award and ... Award. Winners were selected by ASTRO,s Research Evaluation ... Award is awarded to stimulate interest in radiation ...
Cached Medicine News:Health News:Patient safety highlights American Association of Physicists in Medicine 2Health News:Patient safety highlights American Association of Physicists in Medicine 3Health News:Patient safety highlights American Association of Physicists in Medicine 4Health News:Patient safety highlights American Association of Physicists in Medicine 5Health News:Patient safety highlights American Association of Physicists in Medicine 6Health News:Patient safety highlights American Association of Physicists in Medicine 7Health News:Patient safety highlights American Association of Physicists in Medicine 8Health News:Patient safety highlights American Association of Physicists in Medicine 9Health News:Patient safety highlights American Association of Physicists in Medicine 10Health News:Patient safety highlights American Association of Physicists in Medicine 11Health News:Patient safety highlights American Association of Physicists in Medicine 12Health News:Patient safety highlights American Association of Physicists in Medicine 13Health News:Patient safety highlights American Association of Physicists in Medicine 14Health News:Patient safety highlights American Association of Physicists in Medicine 15Health News:Patient safety highlights American Association of Physicists in Medicine 16Health News:Studies explore effects of war on former child soldiers 2Health News:Studies explore effects of war on former child soldiers 3Health News:Studies explore effects of war on former child soldiers 4Health News:New research explores relief for xerostomia cancer patients 2Health News:International AIDS conference features UNC work 2Health News:High Readmission Rates May Not Mean Worse Hospital Care 2Health News:High Readmission Rates May Not Mean Worse Hospital Care 3Health News:5 awarded ASTRO research grants 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: